Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...
Publications
3 shownOlaparib for Metastatic Castration-Resistant Prostate Cancer
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 5,301
- Institution
- Peter MacCallum Cancer Centre
External Links
Identifiers
- ORCID
- 0000-0002-8660-4475
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.